An estimated 75% of people living with dementia are never formally diagnosed. That figure alone tells you something is broken in the current pathway, and it’s not for lack of trying. PET scans and cerebrospinal fluid tests can confirm amyloid pathology with real precision, but they’re expensive, invasive, and largely confined to academic medical centers. Most patients with memory complaints see a primary care physician first, and most primary care physicians have had almost nothing useful to offer at that stage. That is now changing.
On August 24, 2026, the FDA cleared the Elecsys Phospho-Tau (217P) Plasma test, known as pTau217, developed by Roche in collaboration with Eli Lilly. It is the first and only FDA-cleared, single-biomarker blood test cleared to support both rule-in and rule-out assessment of amyloid pathology in adults 55 and older who show signs or symptoms of cognitive decline. The same validated cutoffs apply whether the test is ordered in a community clinic or a specialist center, which matters more than it might sound.
What the test actually does
pTau217 measures a specific phosphorylated form of tau protein in plasma. Elevated levels are associated with amyloid pathology, the hallmark of Alzheimer’s disease. The assay returns one of three result categories: positive, intermediate, or negative. It is not a standalone diagnosis. Results are meant to be interpreted alongside clinical information, cognitive assessments, and other relevant findings as part of a broader diagnostic workup.
In validation studies, the test demonstrated high agreement with amyloid PET imaging in the target population. That’s an important bar, since PET remains the established reference standard for amyloid detection in living patients.
Why consistent cutoffs across care settings matter
One of the more clinically meaningful design choices here is the use of identical cutoffs in primary and specialty care. Historically, blood-based biomarker tools have been developed and validated almost exclusively in specialist populations, then used more broadly without adjustment. Roche and Lilly built this test with both settings in mind from the start, which should reduce the risk of misclassification when a general practitioner orders it.
Roche describes the underlying approach as the “Power of One”: one assay, one biomarker, one set of cutoffs. It’s a deliberate simplification, and in a diagnostic area known for complexity and inconsistency, that’s a reasonable goal.
Infrastructure already in place
The test is designed to run on Roche’s cobas laboratory instruments, with more than 4,500 units already installed across U.S. clinical laboratories. No new equipment is required. That means hospitals and health systems can add pTau217 to existing workflows quickly, without capital investment or lengthy implementation cycles.
For health systems managing growing volumes of patients with cognitive complaints, that matters. Specialist capacity is limited. If a blood test can reliably identify patients with low likelihood of amyloid pathology, those patients can be spared unnecessary referrals. And those with positive results can be fast-tracked to the specialist evaluation or PET imaging that will follow.
What this means for the diagnostic gap
Patients who eventually receive an Alzheimer’s diagnosis typically wait years between first symptoms and confirmation. Much of that delay happens in primary care, where clinicians have lacked tools to act with confidence. A cleared, blood-based test with results interpretable in that setting doesn’t solve every part of that problem, but it removes one of the largest barriers.
Still, expectations should be calibrated. pTau217 is an aid to clinical decision-making, not a replacement for clinical judgment. Intermediate results, which the test will produce in a meaningful share of cases, will require careful management. And the downstream effect on patient outcomes will depend heavily on whether positive results lead to timely access to appropriate care, including approved anti-amyloid therapies where eligible.
- First FDA-cleared blood test supporting both rule-in and rule-out amyloid assessment from a single biomarker
- Same validated cutoffs used in primary and specialty care settings
- Compatible with more than 4,500 cobas instruments already in U.S. labs
- Returns positive, intermediate, or negative result categories
- Validated in adults 55 and older with signs or symptoms of cognitive decline
The broader significance is this: Alzheimer’s diagnosis has long been a bottleneck, concentrated in specialist centers, dependent on expensive imaging, and largely inaccessible to the majority of patients who need it. A cleared blood test that primary care can order and interpret, using the same standards as a memory clinic, is a real step toward fixing that.